随后美国时间5月31日，强生正式宣布完成对ShockWave Medical收购，ShockWave Medical现已成为强生公司的一部分，并将作为强生医疗科技内的一个独立业务部门运营。5月16日，强生宣布将以8.5亿美元现金以及可能的额外的里程碑付款收购Proteologix，这是一家专注于免疫介导疾病双特异性抗体的私营生物技术公司。P
Shockwave Medical, part of Johnson & Johnson MedTech, is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic...
The Scoop: March 26, 2024, 2:18 PM EDT – Johnson & Johnson Considers Deal for Shockwave Medical – WSJ The story as it appeared on Dow Jones: March 26, 2024, 2:18 PM: Johnson & Johnson Considers Deal for Shockwave Medical — WSJ 2:18 PM: *Deal for Shockwave Could be Finalized ...
随后美国时间5月31日,强生正式宣布完成对ShockWave Medical收购,ShockWave Medical现已成为强生公司的一部分,并将作为强生医疗科技内的一个独立业务部门运营。 5月16日,强生宣布将以8.5亿美元现金以及可能的额外的里程碑付款收购Proteologix,这是一...
Shockwave Medical raised a total of $147.5M. Who are the investors of Shockwave Medical? Investors of Shockwave Medical include Johnson & Johnson, Abiomed, T. Rowe Price, Fidelity Investments, Sofinnova Partners and 7 more. Who are Shockwave Medical's competitors? Competitors of Shockwave Medical ...
and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction NEW BRUNSWICK, N.J. and SANTA CLARA, Calif., April 5, 2024– Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have...
Now a part of Johnson & Johnson MedTechDriving the Pulse of Innovation: Breaking Barriers with Sound and More At Shockwave, innovation is in our DNA. We never settle for the status quo and are constantly exploring ways to address unmet clinical needs with low-risk treatment options for ...
Enhances Johnson & Johnson’s Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech’s Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular
随后美国时间5月31日,强生正式宣布完成对ShockWave Medical收购,ShockWave Medical现已成为强生公司的一部分,并将作为强生医疗科技内的一个独立业务部门运营。 5月16日,强生宣布将以8.5亿美元现金以及可能的额外的里程碑付款收购Proteologix,这是一家专注于免疫介导疾病双特异性抗体的私营生物技术公司。
Shockwave Medical Inc (Shockwave), a subsidiary of Johnson & Johnson, is a medical device company that develops and commercializes novel technologies that transform the care of patients with cardiovascular disease. The company specializes in reshaping cardiovascular interventional therapy with intravascular ...